Teva Pharmaceutical to Nominate Four New Directors - WSJ
Earnings Preview: It's a mixed bag for Teva Pharma in Q3 | AlphaStreet
Teva Pharmaceutical Industries — 9 Portfolio companies, 10 Investments, Team — Unicorn Nest
Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth | Ctech
Teva completes $40b purchase of Allergan generics arm | The Times of Israel
Teva Pharmaceutical Industries Adds US$389m To Market Cap, But Investors Still Down 47% From Five Years Ago - Simply Wall St News
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva dispenses $2.6 million to resolve ERISA claims | Pensions & Investments
Teva Reports Second Quarter 2022 Financial Results | Business Wire
Teva Stock Skyrockets After Inking North Of $4 Billion In Opioid Settlements | Investor's Business Daily
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike (NYSE:TEVA) | Seeking Alpha
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Teva Pharmaceuticals will pay $420 million in a federal case
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Capital Research Global Investors increases ownership in TEVJF / Teva Pharmaceutical Industries Ltd.
Buy Teva Pharmaceuticals amid positive news, Bernstein says
Jewish Values Investors JLens Target Israeli Company
Teva Pharmaceutical Stock Could Double | Barron's
Teva Pharmaceuticals Portfolio Investments, Teva Pharmaceuticals Funds, Teva Pharmaceuticals Exits
Report: Teva settles investor lawsuit for $420M - www.israelhayom.com
Investors sue Teva over $41B Actavis deal - Drug Delivery Business
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
